Laurus Labs Limited (NSE:LAURUSLABS)
521.45
-15.30 (-2.85%)
Feb 21, 2025, 3:30 PM IST
Laurus Labs Revenue
Laurus Labs had revenue of 14.15B INR in the quarter ending December 31, 2024, with 18.42% growth. This brings the company's revenue in the last twelve months to 52.73B, up 5.85% year-over-year. In the fiscal year ending March 31, 2024, Laurus Labs had annual revenue of 50.41B, down -16.55%.
Revenue (ttm)
52.73B
Revenue Growth
+5.85%
P/S Ratio
5.34
Revenue / Employee
8.78M
Employees
6,007
Market Cap
281.19B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 50.41B | -10.00B | -16.55% |
Mar 31, 2023 | 60.41B | 11.05B | 22.39% |
Mar 31, 2022 | 49.36B | 1.22B | 2.54% |
Mar 31, 2021 | 48.14B | 19.82B | 69.99% |
Mar 31, 2020 | 28.32B | 5.40B | 23.55% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Laurus Labs News
- 18 days ago - Stocks hitting 52-week high today, February 5: UPL, Laurus Labs, Bajaj Finance, JK Cement and more - Business Upturn
- 24 days ago - Laurus Labs stock jumps 5% after US grants emergency humanitarian waiver for HIV treatment - Business Upturn
- 26 days ago - Laurus Labs shares tumble amid concerns over US foreign aid pause impacting AIDS relief funding. - The Times of India
- 27 days ago - Laurus Labs Ltd (BOM:540222) Q3 2025 Earnings Call Highlights: Strong CDMO Growth Amid ARV ... - GuruFocus
- 27 days ago - Q3 2025 Laurus Labs Ltd Earnings Call Transcript - GuruFocus
- 27 days ago - Laurus Labs clarifies on reports of impact of Antiretroviral business, says no significant impact - Business Upturn
- 27 days ago - Laurus Labs shares fall 10% as ARV funding concerns weigh heavily - Business Upturn
- 4 weeks ago - Laurus Labs Q3 FY25 Financial Results: Revenue up 18.4% YoY to Rs 1415.05 crore, Net Profit up 297% YoY - Business Upturn